The Centers for Medicare & Medicaid Services today repealed a final rule codifying how it defines “reasonable and necessary” coverage for items and services furnished under Medicare Parts A and B, as proposed in September. Scheduled to take effect Dec. 15, the rule also provided an expedited Medicare coverage pathway for certain innovative medical devices designated as breakthrough by the Food and Drug Administration, which CMS said may not have provided sufficient safety protections.  

CMS instead plans to work with the Food and Drug Administration, Agency for Healthcare Research and Quality, medical device makers and other stakeholders to develop an expeditious process to cover innovative devices for Medicare patients, and to hold at least two public meetings in 2022 to inform such policymaking.

In comments submitted on the proposed rule last November, AHA strongly opposed the elevation of definitional guideposts from a manual provision to enforceable standards in the Code of Federal Regulations, especially without a comprehensive assessment of the impact of that change and a clearer articulation of the process by which the new standard would be imposed.

 

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health Sept. 10 advanced the Title VIII Nursing Workforce Reauthorization Act (H.R. 3593), AHA-supported…
Headline
The House Appropriations Committee Sept. 9 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services, Education…
Headline
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Perspective
Public
Congress returns to Washington, D.C., this week facing a long list of things to do, including several that will impact hospitals’ ability to provide access to…
Headline
The AHA Sept. 4 expressed support for the Hospitals As Naloxone Distribution Sites Act (H.R. 5120), legislation that would require Medicare and Medicaid to…